Overview
Upper motor neuron disease encompasses conditions characterized by degeneration of upper motor neurons, leading to symptoms such as muscle weakness, spasticity, and hyperreflexia, often seen in diseases like amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis.Diagnosis
Clinical evaluation focusing on neurological deficits including muscle strength, reflexes, and coordination.
Electromyography (EMG) and nerve conduction studies to assess motor neuron function and peripheral nerve involvement.
MRI or CT scans to rule out other causes of neurological symptoms and assess brain or spinal cord structures.
Cognitive and behavioral assessments to differentiate from other neurodegenerative disorders 1.Management
Riluzole: First-line pharmacological treatment with a dose of 50 mg twice daily, shown to modestly slow disease progression (Evidence: Moderate) 1.
Edaravone: Used in some cases for ALS, though evidence is limited and primarily from observational studies (Evidence: Weak) 1.
Physical therapy and rehabilitation: Essential for maintaining function and quality of life.
Baclofen or tizanidine: Adjunctive treatments for spasticity management (Evidence: Moderate) 1.Special Populations
Elderly: Management focuses on symptom relief and supportive care due to higher comorbidity burden 1.
Comorbidities: Care must be individualized, considering interactions and additional health risks (Evidence: Expert opinion) 1.Key Recommendations
Monitor and manage procedural volume and proficiency in specialized interventions like endoscopic procedures to reduce mortality risk, particularly in cancer patients undergoing upper GI procedures (Evidence: Moderate) 1.
Implement riluzole as first-line pharmacological therapy for slowing disease progression in upper motor neuron diseases like ALS (Evidence: Moderate) 1.
Tailor rehabilitation and supportive care strategies to address specific needs in elderly patients and those with significant comorbidities (Evidence: Expert opinion) 1.References
1 Markar SR, Mackenzie H, Ni M, Huddy JR, Askari A, Faiz O et al.. The influence of procedural volume and proficiency gain on mortality from upper GI endoscopic mucosal resection. Gut 2018. link